Skip to Content
Merck
  • Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Talanta (2012-01-31)
Catarina L Silva, Mário Passos, José S Câmara
ABSTRACT

A sensitive assay to identify volatile organic metabolites (VOMs) as biomarkers that can accurately diagnose the onset of breast cancer using non-invasively collected clinical specimens is ideal for early detection. Therefore the aim of this study was to establish the urinary metabolomic profile of breast cancer patients and healthy individuals (control group) and to explore the VOMs as potential biomarkers in breast cancer diagnosis at early stage. Solid-phase microextraction (SPME) using CAR/PDMS sorbent combined with gas chromatography-mass spectrometry was applied to obtain metabolomic information patterns of 26 breast cancer patients and 21 healthy individuals (controls). A total of seventy-nine VOMs, belonging to distinct chemical classes, were detected and identified in control and breast cancer groups. Ketones and sulfur compounds were the chemical classes with highest contribution for both groups. Results showed that excretion values of 6 VOMs among the total of 79 detected were found to be statistically different (p<0.05). A significant increase in the peak area of (-)-4-carene, 3-heptanone, 1,2,4-trimethylbenzene, 2-methoxythiophene and phenol, in VOMs of cancer patients relatively to controls was observed. Statistically significant lower abundances of dimethyl disulfide were found in cancer patients. Bioanalytical data were submitted to multivariate statistics [principal component analysis (PCA)], in order to visualize clusters of cases and to detect the VOMs that are able to differentiate cancer patients from healthy individuals. Very good discrimination within breast cancer and control groups was achieved. Nevertheless, a deep study using a larger number of patients must be carried out to confirm the results.

MATERIALS
Product Number
Brand
Product Description

Supelco
Melting point standard 121-123°C, analytical standard
Supelco
Benzoic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Hexanal, 98%
Sigma-Aldrich
Benzoic acid, purified by sublimation, ≥99%
Sigma-Aldrich
2-Butanone, FCC, FG
Supelco
(+)-Carvone, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Benzoic acid, Standard for quantitative NMR, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
γ-Terpinene, ≥95.0% (GC)
Supelco
γ-Terpinene, analytical standard
Supelco
2-Heptanone, analytical standard
Supelco
4-Heptanone, analytical standard
Sigma-Aldrich
Benzoic acid, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.9% (alkalimetric)
Supelco
(S)-(−)-Limonene, analytical standard
Supelco
Phenol, PESTANAL®, analytical standard
Supelco
(+)-Carvone, analytical standard
Supelco
Benzoic acid, reference material for titrimetry, certified by BAM, >99.5%
Sigma-Aldrich
Phenol, ≥96.0% (calc. on dry substance, T)
Sigma-Aldrich
Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (GC)
Supelco
2-Butanone, analytical standard
Sigma-Aldrich
Phenol, puriss. p.a., ACS reagent, reag. Ph. Eur., 99.0-100.5%
Sigma-Aldrich
Phenol, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Phenol, BioUltra, for molecular biology, TE-saturated, ~73% (T)
Sigma-Aldrich
γ-Terpinene, 97%
Sigma-Aldrich
(S)-(−)-Limonene, 96%
Sigma-Aldrich
Phenol, unstabilized, ReagentPlus®, ≥99%
Sigma-Aldrich
Dimethyl disulfide, ≥99%
Sigma-Aldrich
Benzoic acid, ≥99.5%, FCC, FG
Sigma-Aldrich
Benzoic acid, natural, ≥99.5%, FCC, FG
Sigma-Aldrich
Dimethyl disulfide, 99%
Sigma-Aldrich
(S)-(+)-Carvone, 96%